Immunotherapy for AIDS patients

Patent 4863730 Issued on September 5, 1989. Estimated Expiration Date:

September 19, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

High titer cytomegalovirus immune serum globulin
Patent #: 4617379
Issued on: 10/14/1986
Inventor: Dobkin , et al.

Intravenously injectable immunoglobulin G (IGG) and method for producing same Patent #: 4639513
Issued on: 01/27/1987
Inventor: Hou , et al.

Inventor

Karpas, Abraham

Application

No. 06/909473 filed on 09/19/1986

US Classes:

424/160.1, Immunodeficiency virus436/547, INVOLVING PRODUCTION OR TREATMENT OF ANTIBODY514/885, IMMUNE RESPONSE AFFECTING DRUG530/388.35, Binds retrovirus or component or product thereof (e.g., HIV, LAV, HTLV, etc.)530/389.4, Binds virus or component or product thereof (e.g., virus-associated antigen, etc.)530/403, Protein is identified as an antigen, e.g., immunogenic carriers, etc.530/806ANTIGENIC PEPTIDES OR PROTEINS

Examiners

Primary: Kight, John
Assistant: Nutter, Nathan M.

Attorney, Agent or Firm

Olstein; Elliot M.

International Classes

A61K 39/42 (20060101)
C07K 16/10 (20060101)
C07K 16/08 (20060101)
A61K 38/00 (20060101)

Abstract

An immunotherapy treatment for a patient infected with the virus giving rise to the acquired immune deficiency syndrome (AIDS) and resulting in a breakdown in the patient's immune response. In this treatment, a supply of plasma is derived from serum-positive individuals who carry the AIDS virus yet are free of the clinical symptons associated with AIDS or with any AIDS-related complex. The plasma supply is processed to provide a preparation rich in antibodies having neutralizing properties in respect to the AIDS virus, the processed plasma being free of red blood cells and other impurities. The processed plasma is transfused intravenously into the infected patient in a dosage which is safe and efficacious, and the transfusion procedure is repeated at spaced intervals of time until the deficiency in the immune response of the patient is substantially overcome.

Other References

Referee's report from the Proceedings of the National Academy of Sciences, U.S.A., on an article by Karpas, et al., "Effects of Passive Immunization in Patients with the AIDS-related Complex and Acquired Immune Deficiency Syndrome.
Stricker et al., "An AIDS-related Cytotoxic Autoantibody Reacts with a Specific Antigen on Stimulated CD4⁺ Cells", Nature, vol. 327, pp. 710-713, Jun. 1987
Walker et al., "CD8⁺ Lymphocytes can Control HIV Infection in Vitro by Suppressing Virus Replication", Science, vol. 234, pp. 1563-1566, Dec. 1986
Karpas et al., "Lytic Infection by British AIDS Virus and Development of Rapid Cell Test for Antiviral Antibodies", The Lancet, Sep. 28, 1985, pp. 695-697